Epigenetics of alcohol-related liver diseases

JHEP Rep. 2022 Mar 10;4(5):100466. doi: 10.1016/j.jhepr.2022.100466. eCollection 2022 May.

Abstract

Alcohol-related liver disease (ARLD) is a primary cause of chronic liver disease in the United States. Despite advances in the diagnosis and management of ARLD, it remains a major public health problem associated with significant morbidity and mortality, emphasising the need to adopt novel approaches to the study of ARLD and its complications. Epigenetic changes are increasingly being recognised as contributing to the pathogenesis of multiple disease states. Harnessing the power of innovative technologies for the study of epigenetics (e.g., next-generation sequencing, DNA methylation assays, histone modification profiling and computational techniques like machine learning) has resulted in a seismic shift in our understanding of the pathophysiology of ARLD. Knowledge of these techniques and advances is of paramount importance for the practicing hepatologist and researchers alike. Accordingly, in this review article we will summarise the current knowledge about alcohol-induced epigenetic alterations in the context of ARLD, including but not limited to, DNA hyper/hypo methylation, histone modifications, changes in non-coding RNA, 3D chromatin architecture and enhancer-promoter interactions. Additionally, we will discuss the state-of-the-art techniques used in the study of ARLD (e.g. single-cell sequencing). We will also highlight the epigenetic regulation of chemokines and their proinflammatory role in the context of ARLD. Lastly, we will examine the clinical applications of epigenetics in the diagnosis and management of ARLD.

Keywords: 3C, chromosome conformation capture; 4C, chromosome conformation capture-on-chip; AH, alcohol-related hepatitis; ARLD, alcohol-related liver disease; ASH, alcohol-related steatohepatitis; ATAC, assay for transposase-accessible chromatin; Acetylation; Alcohol liver disease; BET, bromodomain and extraterminal motif; BETi, BET inhibitor; BRD, bromodomain; CCL2, C-C motif chemokine ligand 2; CTCF, CCCTC-binding factor; CXCL, C-X-C motif chemokine ligand; Chromatin architecture; Computational biology; DNA methylation; DNMT, DNA methyltransferase; E-P, enhancer-promoter; Epidrugs; Epigenetics; FKBP5, FK506-binding protein 5; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; HIF1α, hypoxia inducible factor-1α; HMGB1, high-mobility group box protein 1; HNF4α, hepatocyte nuclear factor 4α; HSC, hepatic stellate cell; Hi-C, chromosome capture followed by high-throughput sequencing; Histones; IL, interleukin; LPS, lipopolysaccharide; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MECP2, methyl-CpG binding protein 2; NAFLD, non-alcohol-related fatty liver disease; PPARG, peroxisome proliferator activated receptor-γ; SAA, salvianolic acid A; SIRT, sirtuin; SREBPs, sterol regulatory element-binding proteins; Single cell epigenome; TAD, topologically associating domain; TEAD, TEA domain transcription factor; TLR, Toll-like receptor; TNF, tumour necrosis factor; YAP, Yes-associated protein; lncRNA, long non-coding RNA; miRNA, microRNA.

Publication types

  • Review